$ABUS Part 2 continued.....Genevant is licensing out this technology to BNTX. BNTX is working with PFE to develop their Covid-19 vaccine almsot certainly using this technology. So ABUS has the high probability of being the foundation of 2 different leading Covid-19 vaccines. This is HUGE! Puts in play a potential buyout from BNTX AND PFE for this patented LNP technology in addition to MRNA. Too good to be true? See below link of proof of agreement. businesswire.com/news/home/... Genevant’s LNP platform is the only clinically-validated LNP delivery technology, the safety and efficacy of which has been evaluated in over 400 patients across multiple clinical programs. Genevant’s delivery technologies can facilitate therapeutic approaches covering a broad spectrum of payloads. Genevant has begun development on numerous programs across multiple RNA modalities. Genovant/ ABUS relationship: ih.advfn.com/stock-market/N...
  • 1
1 Like